THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.35]-C177 ID: TIP-MED-000447

Equine / Human Rabies Immunoglobulin (eRIG/hRIG)

Active Ingredient / Scientific Identity: Equine / Human Rabies Immunoglobulin • Class: Inactivated Cell-Culture Rabies Vaccine (Active Immunisation) & Passive Anti-Rabies Immunoglobulin / Monoclonal Antibody

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Equine / Human Rabies Immunoglobulin (eRIG/hRIG) ([12.35]-C177 | ID: TIP-MED-000447) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/12-35-c177-equine-human-rabies-immunoglobulin-erig-hrig/
Generic / Entity NameEquine / Human Rabies Immunoglobulin (eRIG/hRIG) ([12.35]-C177)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassInactivated Cell-Culture Rabies Vaccine (Active Immunisation) & Passive Anti-Rabies Immuno
Available Dosage FormsCell-Culture Vaccine (PCEC / PVRV): >=2.5 IU per reconstituted vial (0.5 mL or 1.0 mL); Equine RIG (eRIG): 300
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No adjustment. • Hepatic: No adjustment.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Equine / Human Rabies Immunoglobulin (eRIG/hRIG) (TIP-MED-000447, Reference Code [12.35]-C177) is classified under Vaccines, Immunologicals & Emergency Toxicology Antidotes (Ch 12) as a Inactivated Cell-Culture Rabies Vaccine (Active Immunisation) & Passive Anti-Rabies Immunoglobulin / Monoclonal Antibody. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [12.35] (Rabies Vaccine (ID/IM Cell-Culture) & Rabies Immunoglobulin (RIG)). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.35], p. 172): Rabipur (PCEC), Abhayrab, Verorab (PVRV), Vaxirab-N; RIG/RmAb: Rabishield, Twinrab, Equirab — Strengths & Dosage Forms: Cell-Culture Vaccine (PCEC / PVRV): >=2.5 IU per reconstituted vial (0.5 mL or 1.0 mL); Equine RIG (eRIG): 300 IU/mL; Human RIG (hRIG): 150 IU/mL; Human Rabies mAb (Rabishield): 40 IU/mL or 100 IU/mL.
Co-indexed constituent under primary monograph [12.35] (Rabies Vaccine (ID/IM Cell-Culture) & Rabies Immunoglobulin (RIG)). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.35], p. 172): Rabipur (PCEC), Abhayrab, Verorab (PVRV), Vaxirab-N; RIG/RmAb: Rabishield, Twinrab, Equirab — Strengths & Dosage Forms: Cell-Culture Vaccine (PCEC / PVRV): >=2.5 IU per reconstituted vial (0.5 mL or 1.0 mL); Equine RIG (eRIG): 300 IU/mL; Human RIG (hRIG): 150 IU/mL; Human Rabies mAb (Rabishield): 40 IU/mL or 100 IU/mL.
Dosage Forms & Available Strengths:
Cell-Culture Vaccine (PCEC / PVRV): >=2.5 IU per reconstituted vial (0.5 mL or 1.0 mL); Equine RIG (eRIG): 300 IU/mL; Human RIG (hRIG): 150 IU/mL; Human Rabies mAb (Rabishield): 40 IU/mL or 100 IU/mL.
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Vaccine induces neutralising anti-rabies glycoprotein antibodies (protective titre >=0.5 IU/mL by Day 7–14); Rabies Immunoglobulin (RIG) or Rabies Monoclonal Antibody (RmAb) infiltrated directly into the wound provides immediate local passive virus neutralisation during the 7-day window before vaccine antibodies appear.

4. Therapeutic Indications & Evidence-Supported Uses

  • Post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) against Rabies virus following animal bites, scratches, or mucosal licks (dogs, cats, monkeys, bats, wild carnivores)
  • Rabies is 100% fatal once clinical symptoms appear, and 100% preventable with timely PEP!

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: MoHFW / NCDC National Rabies Control Programme Regimens: (1) Updated Thai Red Cross Intradermal (ID) Regimen (2-2-2-0-2): 0.1 mL ID at TWO sites (left and right deltoid) on Days 0, 3, 7, and 28. (2) Essen Intramuscular (IM) Regimen (1-1-1-1-1): 1 full vial (0.5 mL or 1 mL) IM into deltoid on Days 0, 3, 7, 14, and 28. For Category III exposures (any transdermal bite/scratch that draws blood, or saliva on mucous membrane/broken skin) in previously unvaccinated patients: ALSO infiltrate eRIG (40 IU/kg) or hRIG (20 IU/kg) or Rabishield mAb (3.33 IU/kg) thoroughly into and around all wounds on Day 0! • Paediatric: IDENTICAL VACCINE DOSE AND SCHEDULE TO ADULTS! Administer IM into the anterolateral thigh in infants/young children (<2 years) or deltoid in older children—NEVER inject Rabies Vaccine into the gluteal region (buttock)! RIG/RmAb is dosed by kg body weight.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [12.35].
Metabolism & Biotransformation:
Renal: No adjustment. • Hepatic: No adjustment.
Elimination & Renal Adjustment:
Renal: No adjustment. • Hepatic: No adjustment.
Hepatic Impairment Considerations:
Renal: No adjustment. • Hepatic: No adjustment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: POST-EXPOSURE PROPHYLAXIS HAS ZERO CONTRAINDICATIONS (including pregnancy, infancy, lactation, intercurrent illness, or immunocompromised state) because clinical rabies is universally fatal! • Precautions: MANDATORY IMMEDIATE WOUND WASHING: Wash all bite/scratch wounds vigorously under running water with soap/detergent for a full 15 MINUTES, then apply Povidone-Iodine or 70% Alcohol; do NOT tightly suture animal bite wounds immediately (if surgical apposition is unavoidable, infiltrate RIG/RmAb into the wound bed FIRST and place loose sutures hours later). Never administer RIG into the same syringe or same anatomical site as the Rabies Vaccine. Do NOT give RIG if >7 days have elapsed since the first vaccine dose (active antibody response has already begun).

Key Clinical Precautions: Renal: No adjustment. • Hepatic: No adjustment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Mild injection-site pain, erythema, induration, low-grade fever, headache, myalgia.
  • Rare allergic reaction or serum sickness (with equine RIG).
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Chloroquine / Hydroxychloroquine / High-dose Corticosteroids / Immunosuppressants -> may blunt intradermal vaccine response (use the Intramuscular regimen in immunocompromised patients and verify Day-14 neutralising antibody titre >=0
    • 5 IU/mL)

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.35].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Wash the wound immediately with soap and running water for 15 minutes (do NOT apply chilly powder, lime, oil, or soil on the wound); never miss any scheduled vaccination dates (Days 0, 3, 7, 14, 28); pregnancy and breastfeeding are completely safe for the vaccine.
    • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / MoHFW-NCDC National Rabies Guidelines

    Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    ← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
    Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/12-35-c177-equine-human-rabies-immunoglobulin-erig-hrig/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.